Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis

Januar Wibawa Martha, Arief Wibowo, Raymond Pranata, Januar Wibawa Martha, Arief Wibowo, Raymond Pranata

Abstract

Purpose: This meta-analysis aimed to evaluate the prognostic performance of elevated lactate dehydrogenase (LDH) in patients with COVID-19.

Methods: A systematic literature search was performed using PubMed, Embase and EuropePMC on 19 November 2020. The outcome of interest was composite poor outcome, defined as a combined endpoint of mortality, severity, need for invasive mechanical ventilation and need for intensive care unit care. Severity followed the included studies' criteria.

Results: There are 10 399 patients from 21 studies. Elevated LDH was present in 44% (34%-53%) of the patients. Meta-regression analysis showed that diabetes was correlated with elevated LDH (OR 1.01 (95% CI 1.00 to 1.02), p=0.038), but not age (p=0.710), male (p=0.068) and hypertension (p=0.969). Meta-analysis showed that elevated LDH was associated with composite poor outcome (OR 5.33 (95% CI 3.90 to 7.31), p<0.001; I2: 77.5%). Subgroup analysis showed that elevated LDH increased mortality (OR 4.22 (95% CI 2.49 to 7.14), p<0.001; I2: 89%). Elevated LDH has a sensitivity of 0.74 (95% CI 0.60 to 0.85), specificity of 0.69 (95% CI 0.58 to 0.78), positive likelihood ratio of 2.4 (95% CI 1.9 to 2.9), negative likelihood ratio of 0.38 (95% CI 0.26 to 0.55), diagnostic OR of 6 (95% CI 4 to 9) and area under curve of 0.77 (95% CI 0.73 to 0.80). Elevated LDH would indicate a 44% posterior probability and non-elevated LDH would in indicate 11% posterior probability for poor prognosis. Meta-regression analysis showed that age, male, hypertension and diabetes did not contribute to the heterogeneity of the analyses.

Conclusion: LDH was associated with poor prognosis in patients with COVID-19.

Prospero registration number: CRD42020221594.

Keywords: COVID-19; adult intensive & critical care; intensive & critical care.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
PRISMA flow chart. LDH, lactate dehydrogenase; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 2
Figure 2
Forest-plot for lactate dehydrogenase and composite poor outcome. LDH, lactate dehydrogenase.
Figure 3
Figure 3
Pooled sensitivity and specificity. LDH, lactate dehydrogenase.
Figure 4
Figure 4
Summary receiver operating characteristics (SROC) curve . AUC, area under curve; SROC, summary receiver operating characteristic
Figure 5
Figure 5
Fagan’s normogram. LR, likelihood ratio.
Figure 6
Figure 6
Univariable meta-regression and subgroup analyses.

References

    1. World Health Organization Weekly epidemiological update: coronavirus 08 December 2020. Geneva, 2020. Available:
    1. Lim MA, Pranata R, Huang I, et al. . Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis. Can J Kidney Health Dis 2020;7:205435812093857.10.1177/2054358120938573
    1. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2020;14:395–403.10.1016/j.dsx.2020.04.018
    1. Lu J, Wei Z, Jiang H, et al. . Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study. J Surg Res 2018;228:314–21.10.1016/j.jss.2018.03.035
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.10.1016/S0140-6736(20)30183-5
    1. Kang HE, Park DW. Lactate as a biomarker for sepsis prognosis? Infect Chemother 2016;48:252.10.3947/ic.2016.48.3.252
    1. Duman A, Akoz A, Kapci M, et al. . Prognostic value of neglected biomarker in sepsis patients with the old and new criteria: predictive role of lactate dehydrogenase. Am J Emerg Med 2016;34:2167–71.10.1016/j.ajem.2016.06.012
    1. Zhang J, Wang X, Jia X, et al. . Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect 2020;26:767–72.10.1016/j.cmi.2020.04.012
    1. Chen G, Wu D, Guo W, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620–9.10.1172/JCI137244
    1. Chen Z, Zhang F, Hu W. Laboratory markers associated with COVID‐19 progression in patients with or without comorbidity: a retrospective study. J Clin Lab Anal 2020:1–12.
    1. Colaneri M, Sacchi P, Zuccaro V, et al. . Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill 2020;25:1–6.10.2807/1560-7917.ES.2020.25.16.2000460
    1. Deng M, Qi Y, Deng L, et al. . Obesity as a potential predictor of disease severity in young COVID-19 patients: a retrospective study. Obesity 2020;28:1815–25.10.1002/oby.22943
    1. Guan W-J, Z-Y N, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020:1–13.
    1. Hong KS, Lee KH, Chung JH, et al. . Clinical features and outcomes of 98 patients hospitalized with sars-cov-2 infection in Daegu, South Korea: a brief descriptive study. Yonsei Med J 2020;61:431–7.10.3349/ymj.2020.61.5.431
    1. Huang Y, Lyu X, Li D, et al. . A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19. PLoS One 2020;15:e0242045. 10.1371/journal.pone.0242045
    1. Jang JG, Hur J, Choi EY. Prognostic factors for severe coronavirus disease 2019 in Daegu, Korea. J Korean Med Sci 2020;35:1–10.
    1. Khamis F, Al-Zakwani I, Al Naamani H, et al. . Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: an experience from Oman. J Infect Public Health 2020;13:906–13.10.1016/j.jiph.2020.06.002
    1. Li L, Zhang S, He B, et al. . Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID-19. Clin Cardiol 2020;43:1624–30.10.1002/clc.23492
    1. Li X, Xu S, Yu M, et al. . Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110–8.10.1016/j.jaci.2020.04.006
    1. Mikami T, Miyashita H, Yamada T, et al. . Risk factors for mortality in patients with COVID-19 in New York City. J Gen Intern Med 2020. doi:10.1007/s11606-020-05983-z. [Epub ahead of print: 30 Jun 2020].
    1. Ramos-Rincon J-M, Buonaiuto V, Ricci M. Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain. J Gerontol A Biol Sci Med Sci 2020:1–10.10.1093/gerona/glaa243
    1. Wang F, Hou H, Luo Y, et al. . The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight 2020;5:5.10.1172/jci.insight.137799
    1. Wang Y, Liao B, Guo Y, et al. . Clinical characteristics of patients infected with the novel 2019 coronavirus (SARS-Cov-2) in Guangzhou, China. Open Forum Infect Dis 2020;7:1–7.10.1093/ofid/ofaa187
    1. Wei Y, Zeng W, Huang X, et al. . Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu district, Hubei Province: a single-center descriptive study. BMC Infect Dis 2020;20:549. 10.1186/s12879-020-05252-8
    1. Zhang S-Y, Lian J-S, Hu J-H, et al. . Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty 2020;9:1–10.10.1186/s40249-020-00710-6
    1. Zheng F, Tang W, Li H, et al. . Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 2020;24:3404–10.10.26355/eurrev_202003_20711
    1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.10.1016/S0140-6736(20)30566-3
    1. Wu Y, Dong Y, Atefi M, et al. . Lactate, a neglected factor for diabetes and cancer interaction. Mediators Inflamm 2016;2016:1–12.10.1155/2016/6456018
    1. Avogaro A, Toffolo G, Miola M, et al. . Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals. J Clin Invest 1996;98:108–15.10.1172/JCI118754
    1. Del Prato S, Bonadonna RC, Bonora E, et al. . Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest 1993;91:484–94.10.1172/JCI116226
    1. Thorburn AW, Gumbiner B, Bulacan F, et al. . Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 1990;85:522–9.10.1172/JCI114468
    1. Erez A, Shental O, Tchebiner JZ, et al. . Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. Isr Med Assoc J 2014;16:439–43.
    1. Huang I, Pranata R, Lim MA, et al. . C-Reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis 2020;14:175346662093717 10.1177/1753466620937175
    1. Pranata R, Lim MA, Yonas E, et al. . Body mass index and outcome in patients with COVID-19: a dose-response meta-analysis. Diabetes Metab 2020. doi:10.1016/j.diabet.2020.07.005. [Epub ahead of print: 29 Jul 2020].
    1. Pranata R, Huang I, Lim MA, et al. . Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19–systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis 2020;29:104949.10.1016/j.jstrokecerebrovasdis.2020.104949
    1. Pranata R, Lim MA, Huang I, et al. . Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin-Angiotensin-Aldosterone Syst 2020;21:147032032092689.10.1177/1470320320926899
    1. Pranata R, Henrina J, Lim MA, et al. . Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr 2020;93:104324. 10.1016/j.archger.2020.104324
    1. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care 2020;8:36.10.1186/s40560-020-00453-4
    1. Huang I, Pranata R, Lim MA, et al. . C-Reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis 2020;14:175346662093717. 10.1177/1753466620937175
    1. Pranata R, Permana H, Huang I, et al. . The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:983–90.10.1016/j.dsx.2020.06.047
    1. Lukito AA, Pranata R, Henrina J, et al. . The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:2177–83.10.1016/j.dsx.2020.11.006

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅